Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases

Nature Reviews Genetics

Volumn 17, Issue 5, 2016, Pages 300-312

  Tsai, Shengdar Q ^a,b   Joung, J Keith ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEASE; DNA; ENDONUCLEASE;

ARTICLE; CRISPR CAS SYSTEM; DNA CLEAVAGE; GENE TARGETING; GENOME ANALYSIS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; GENETIC ENGINEERING; GENETICS; HUMAN; HUMAN GENOME; METABOLISM;

CRISPR-CAS SYSTEMS; DNA; ENDONUCLEASES; GENETIC ENGINEERING; GENOME, HUMAN; HUMANS;

EID: 84964253170     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2016.28     Document Type: Article

References (95)

1. Doetschman T, et al. Targeted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature. 330, 576-578 (1987).
2. Thomas K. R, & Capecchi M. R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 51, 503-512 (1987).
3. Evans M. J, & Kaufman M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature. 292, 154-156 (1981).
4. The 2007 Nobel Prize in Physiology or Medicine - Press Release. Nobelprize.org [online], http://www.nobelprize.org/nobel-prizes/medicine/.laureates/2007/press.html
5. Rouet P, Smih F, & Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol. Cell. Biol. 14, 8096-8106 (1994).
6. Silva G, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr. Gene Ther. 11, 11-27 (2011).
7. Urnov F. D, Rebar E. J, Holmes M. C, Zhang H. S, & Gregory P. D. Genome editing with engineered zinc finger nucleases. Nature. 11, 636-646 (2010).
8. Sander J. D, & Joung J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347-355 (2014).
9. Hsu P. D, Lander E. S, & Zhang F. Development and applications of CRISPR Cas9 for genome engineering. Cell. 157, 1262-1278 (2014).
10. Doudna J. A, & Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR Cas9. Science. 346, 1258096 (2014).
11. Kim Y. G, Cha J, & Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl Acad. Sci. USA. 93, 1156-1160 (1996).
12. Cermak T, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011).
13. Li T, et al. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res. 39, 6315-6325 (2011).
14. Bitinaite J, Wah D. A, Aggarwal A. K, & Schildkraut I. FokI dimerization is required for DNA cleavage. Proc. Natl Acad. Sci. USA. 95, 10570-10575 (1998).
15. Wah D. A, Bitinaite J, Schildkraut I, & Aggarwal A. K. Structure of FokI has implications for DNA cleavage. Proc. Natl Acad. Sci. USA. 95, 10564-10569 (1998).
16. Boissel S, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 42, 2591-2601 (2014).
17. Jinek M, et al A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 337, 816-821 (2012).
18. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 339, 823-826 (2013).
19. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 339, 819-823 (2013).
20. Jinek M, et al. RNA-programmed genome editing in human cells. eLife. 2, e00471 (2013).
21. Hwang W. Y, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227-229 (2013).
22. Ran F. A, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 520, 186-191 (2015).
23. Hou Z, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl Acad. Sci. USA. 110, 15644-15649 (2013).
24. Zhang X. H, Tee L. Y, Wang X. G, Huang Q. S, & Yang S. H. Off-Target effects in CRISPR/Cas9 mediated genome engineering. Mol. Ther. Nucleic Acids. 4, e264 (2015).
25. Pattanayak V, Guilinger J. P, & Liu D. R. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods Enzymol. 546, 47-78 (2014).
26. OGeen H, Yu A. S, & Segal D. J. How specific is CRISPR/Cas9 really?. Curr. Opin. Chem. Biol. 29, 72-78 (2015).
27. LaFountaine J. S, Fathe K, & Smyth H. D. C. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int. J. Pharm. 494, 180-194 (2015).
28. Jamal M, et al. Keeping CRISPR/Cas on target. Curr. Issues Mol. Biol. 20, 1-20 (2015).
29. Ishida K, Gee P, & Hotta A. Minimizing off-Target mutagenesis risks caused by programmable nucleases. Int. J. Mol. Sci. 16, 24751-24771 (2015).
30. Bolukbasi M. F, Gupta A, & Wolfe S. A. Creating and evaluating accurate CRISPR Cas9 scalpels for genomic surgery. Nat. Methods. 13, 41-50 (2015).
31. Yang H, et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. 154, 1370-1379 (2013).
32. Cho S. W, et al. Analysis of off-Target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132-141 (2014).
33. Liang X, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44-53 (2015).
34. Pattanayak V, et al. High-Throughput profiling of off-Target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839-843 (2013).
35. Fu Y, et al. High-frequency off-Target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
36. Hsu P. D, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827-832 (2013).
37. Cradick T. J, Fine E. J, Antico C. J, & Bao G. CRISPR/Cas9 systems targeting β globin and CCR5 genes have substantial off-Target activity. Nucleic Acids Res. 41, 9584-9592 (2013).
38. Lin Y, et al. CRISPR/Cas9 systems have off-Target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473-7485 (2014).
39. Zhang H, et al. The CRISPR/Cas9 system produces specific and homozygous targeted gene editing in rice in one generation. Plant Biotechnol. J. 12, 797-807 (2014).
40. Gasiunas G, Barrangou R, Horvath P, & Siksnys V. Cas9 crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl Acad. Sci. USA. 109, E2579-E2586 (2012).
41. Cho S. W, Kim S, Kim J. M, & Kim J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230-232 (2013).
42. Heigwer F, Kerr G, & Boutros M. E CRISP: fast CRISPR target site identification. Nat. Methods. 11, 122-123 (2014).
43. Pattanayak V, Ramirez C. L, Joung J. K, & Liu D. R. Revealing off-Target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods. 8, 765-770 (2011).
44. Guilinger J. P, et al. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods. 11, 429-435 (2014).
45. Sander J. D, et al. In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-Target sites. Nucleic Acids Res. 41, e181 (2013).
46. Smith C, et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell. 15, 12-13 (2014).
47. Veres A, et al. Low incidence of off-Target mutations in individual CRISPR Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell. 15, 27-30 (2014).
48. Iyer V, et al. Off-Target mutations are rare in Cas9 modified mice. Nat. Methods. 12, 479-479 (2015).
49. Tsai S. Q, & Joung J. K. Whats changed with genome editing?. Cell Stem Cell. 15, 3-4 (2014).
50. Gabriel R, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29, 816-823 (2011).
51. Osborn M. J, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9 and megaTAL nucleases. Mol. Ther. 24, 570-581 (2016).
52. Wang X, et al. Unbiased detection of off-Target cleavage by CRISPR Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175-178 (2015).
53. Tsai S. Q, et al. GUIDE-seq enables genome-wide profiling of off-Target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187-197 (2015).
54. Tsai S. Q, Topkar V. V, Joung J. K, & Aryee M. J. Open-source software guideseq for analysis of GUIDE-seq data. Nat. Biotechnol. (in the press).
55. Chiarle R, et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell. 147, 107-119 (2011).
56. Frock R. L, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33, 179-186 (2015).
57. Crosetto N, et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat. Methods. 10, 361-365 (2013).
58. Kim D, et al. Digenome-seq: genome-wide profiling of CRISPR Cas9 off-Target effects in human cells. Nat. Methods. 12, 237-243 (2015).
59. Kim D, Kim S, Kim S, Park J, & Kim J. S. Genome-wide target specificities of CRISPR Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res. http://dx.doi.org/10.1101/.gr.199588.115 (2016).
60. Fu Y, Sander J. D, Reyon D, Cascio V. M, & Joung J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279-284 (2014).
61. Ran F. A, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 154, 1380-1389 (2013).
62. Mali P, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013).
63. Tsai S. Q, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32, 569-576 (2014).
64. Guilinger J. P, Thompson D. B, & Liu D. R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32, 577-582 (2014).
65. Wyvekens N, Topkar V. V, Khayter C, Joung J. K, & Tsai S. Q. Dimeric CRISPR RNA-guided FokI dCas9 nucleases directed by truncated gRNAs for highly specific genome editing. Hum. Gene Ther. 26, 425-431 (2015).
66. Hara S, et al. Generation of mutant mice via the CRISPR/Cas9 system using FokI dCas9. Sci. Rep. 5, 11221 (2015).
67. Nakagawa Y, et al. Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-Thawed fertilized oocytes. BMC Biotechnol. 15, 33 (2015).
68. Kleinstiver B. P, et al. High-fidelity CRISPR Cas9 nucleases with no detectable genome-wide off-Target effects. Nature. 529, 490-495 (2016).
69. Slaymaker I. M, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 351, 84-88 (2016).
70. Anders C, Niewoehner O, Duerst A, & Jinek M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 513, 569-573 (2014).
71. Jinek M, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 343, 1247997 (2014).
72. Nishimasu H, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 156, 935-949 (2014).
73. Kim S, Kim D, Cho S. W, Kim J, & Kim J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012-1019 (2014).
74. Zuris J. A, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73-80 (2015).
75. Gaj T, Guo J, Kato Y, Sirk S. J, & Barbas C. F. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods. 9, 805-807 (2012).
76. Wright A. V, et al. Rational design of a split Cas9 enzyme complex. Proc. Natl Acad. Sci. USA. 112, 2984-2989 (2015).
77. Zetsche B, Volz S. E, & Zhang F A split Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33, 139-142 (2015).
78. Nihongaki Y, Kawano F, Nakajima T, & Sato M. Photoactivatable CRISPR Cas9 for optogenetic genome editing. Nat. Biotechnol. 33, 755-760 (2015).
79. Davis K. M, Pattanayak V, Thompson D. B, Zuris J. A, & Liu D. R. Small molecule-Triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 11, 316-318 (2015).
80. Jiang F, Zhou K, Ma L, Gressel S, & Doudna J. A A Cas9 guide RNA complex preorganized for target DNA recognition. Science. 348, 1477-1481 (2015).
81. Knight S. C, et al. Dynamics of CRISPR Cas9 genome interrogation in living cells. Science. 350, 823-826 (2015).
82. Sternberg S. H, Redding S, Jinek M, Greene E. C, & Doudna J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 507, 62-67 (2014).
83. Kleinstiver B. P, et al. Engineered CRISPR Cas9 nucleases with altered PAM specificities. Nature. 523, 481-485 (2015).
84. Kleinstiver B. P, et al. Broadening the targeting range of Staphylococcus aureus CRISPR Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293-1298 (2015).
85. Hirano H, et al. Structure and engineering of Francisella novicida Cas9. Cell. 164, 950-961 (2016).
86. Bolukbasi M. F, et al. DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat. Methods. 12, 1150-1156 (2015).
87. Sternberg S. H, LaFrance B, Kaplan M, & Doudna J. A. Conformational control of DNA target cleavage by CRISPR Cas9. Nature. 527, 110-113 (2015).
88. Jiang F, et al. Structures of a CRISPR Cas9 R loop complex primed for DNA cleavage. Science. 351, 867-871 (2016).
89. Kiani S, et al. Cas9 gRNA engineering for genome editing, activation and repression. Nat. Methods. 12, 1051-1054 (2015).
90. Dahlman J. E, et al. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat. Biotechnol. 33, 1159-1161 (2015).
91. Yang L, et al. Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nat. Commun. 5, 5507 (2014).
92. Deltcheva E, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 471, 602-607 (2011).
93. Wu X, et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32, 670-676 (2014).
94. Cencic R, et al. Protospacer adjacent motif (PAM)- distal sequences engage CRISPR Cas9 DNA target cleavage. PLoS ONE. 9, e109213 (2014).
95. OGeen H, Henry I. M, Bhakta M. S, Meckler J. F, & Segal D. J A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. Nucleic Acids Res. 43, 3389-3404 (2015).